RBC Capital analyst Brandon Henry writes that the findings from his Radiation Oncologist survey suggest Accuray "can execute on its replacement cycle opportunity", but the company has to do more to convince the practitioners outside its installed base that its systems are sufficiently differentiated. Henry adds that the replacement cycle opportunity for Accuray's CyberKnife remains intact, with a more positive response rate by oncologists in Europe, though U.S. oncologists were less enthused in their response. The analyst keeps his Sector Perform rating and $6 price target on Accuray, forecasting the stock to perform in line with its peer group.